The development of first-generation recombinant therapeutic proteins through genetic engineering and the production of therapeutically effective monoclonal antibodies (mAbs) are considered major ...

Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, ...

Panelists discuss how employers optimize biosimilar uptake through strategic formulary design, financial incentives, and provider education, enabling health care systems to achieve substantial ...

To gain approval by the the Food and Drug Administration, biosimilars must demonstrate that they are highly similar in molecular structure and have no clinically meaningful differences in safety ...

A biosimilar medicine is a medicine that has a similar, but not identical, active ingredient to the reference (first) medicine. Because of this, a biosimilar should be thought of as being a medicine ...

Biosimilars, approved copies of these biological medications, are high quality, similar, and less expensive medicines than the reference biologic and can play an important role in addressing this ...

If so, this doesn’t bode well for biosimilars gaining much traction ... Ultimately, the “warped incentive structure” in the U.S. is good for PBMs, but not for patients.

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

The UK health service has well over a decade’s experience of dealing with biosimilars, but the NHS acknowledges that it has yet to make the most of these drugs. That was certainly one of the ...